GENE ONLINE|News &
Opinion
Blog

Checkpoint Inhibitor
EQRx, CStone’s Low-Cost anti-PD-L1 Inhibitor Flaunts Encouraging Data in Stage 3 NSCLC
2021-09-19
MD Anderson to Develop Microbiome Cancer Therapeutics with CRISPR Gene-Editing
2021-09-14
Day 4 ASCO 2021 Roundup: Immunotherapy Candidates Show Promise in Early Studies
2021-06-09
Day 3 ASCO 2021 Roundup: Lynparza, Keytruda and Novartis’ Radioligand Therapy Take Honors in Plenary Session
2021-06-09
Amgen, Kyowa Kirin Renew Long-Standing Partnership to Promote Atopic Dermatitis Therapy
2021-06-02
A Glance at Gene Therapy Advances in Cancer
2021-05-16
AstraZeneca Voluntarily Withdraws Checkpoint Inhibitor Approved for Bladder Cancer Indication
2021-02-25
Another Checkpoint Inhibitor Set to Make Market Appearance as FDA Grants Priority Review
2021-01-25
Bristol Myers Squibb to Acquire Forbius for Augmenting TGF-beta Inhibitors
2020-08-25
A Novel Tool to Augment Checkpoint Inhibitor Cancer Therapy
2020-08-19
Weekly in Asia(0421-0427 )
2019-04-30
LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top